Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 23 August 2018

Indication(s)

This medicinal product is for diagnostic use only.

DaTSCAN is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:

- In adult patients with clinically uncertain Parkinsonian Syndromes, for example those with early symptoms, in order to help differentiate Essential Tremor from Parkinsonian Syndromes related to idiopathic Parkinson’s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy.
DaTSCAN is unable to discriminate between Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy.
- In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease.
DaTSCAN is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

EPNS 2019 Congress Highlights

EPNS 2019 Congress Highlights

The epgonline.org team is creating daily reports from the 13th European Paediatric Neurology Society (EPNS) Congress, held in Athens, Greece from 17th to 21st September 2019, to bring you coverage of cutting-edge science and advances in clinical care across all fields of paediatric neurology. 

COMT inhibition in Parkinson's Disease

COMT inhibition in Parkinson's Disease

The COMT inhibition in Parkinson's Disease Learning Zone contains key information, expert opinion and interactive learning to highlight the benefit to patients of early levodopa treatment and diagnosis of the motor fluctuations which signal disease progression and prompt adjunctive treatment. Also deatiling key efficacy and safety data for the approved COMT inhibitors to help inform your treatment decisions. 

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000266
Orphan designation No
Date First Approved 27-07-2000
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder GE Healthcare Limited